Irinotecan Plus Carboplatin Versus Oral Etoposide Plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial

Abstract

IC prolongs survival in ED SCLC with slightly better scores for QOL.

The humanistic burden of small cell lung cancer (SCLC): a systematic review of health-related quality of life (HRQoL) literature

“…SCLC patients (both ED and LD) who had responded to treatment (67, Bottomley et al, 2008;Slotman et al, 2009) reported higher scores than patients who had not been treated. Systemic treatment naïve ED SCLC patients had the lowest scores overall (44.7, Hermes et al, 2008). As expected, all SCLC EORTC QLQ-C30 scores were lower the normative global health status/QoL scores provided by the EORTC of 71.2 (Scott et al, 2008).…”

“…The 27 publications included in this review reported results from interventional clinical trials assessing HRQoL as an endpoint (n = 18); 11 were randomized but not controlled (Thatcher et al, 2005;Eckardt et al, 2006;Reck et al, 2006Reck et al, , 2012Hermes et al, 2008;Lee et al, 2009;Le Pechoux et al, 2011;Nagel et al, 2011;Wolfson et al, 2011;Satouchi et al, 2014;Sekine et al, 2014) (see Table 2), four were randomized controlled trials (RCTs) (Giaccone et al, 2005;O'Brien et al, 2006;Bottomley et al, 2008;Slotman et al, 2009) (see Table 3) and three were nonrandomized interventional studies (Fennell et al, 2007;Araujo et al, 2009;Eckardt et al, 2009) (see Table 4). The remaining publications were real world (n = 7) (Jatoi et al, 2005;Chen et al, 2007Chen et al, , 2008Chen et al, , 2012Rolke et al, 2008;Kohli et al, 2010;Nakahara et al, 2015) (see Table 5) and mixed-methods studies (n = 2) (Westerman et al, 2007(Westerman et al, , 2008) (see Table 6).…”

“…Real world EORTC QLQ-C30 data could be drawn from one study only, reporting a mean score of 49.6 (Rolke et al, 2008). This score falls within the range of clinical trial EORTC QLQ-C30 baseline scores (Reck et al, 2006;Bottomley et al, 2008;Hermes et al, 2008;Lee et al, 2009;Slotman et al, 2009), indicating no difference in scores between the population types.…”

“…In the LCSS, the second most frequently used PRO to measure the concept (n = 4, 19%, Jatoi et al, 2005;Eckardt et al, 2006Eckardt et al, , 2009Chen et al, 2012), global QoL is assessed via a single item. Most chemotherapy naïve LD and ED SCLC patients had EORTC QLQ-C30 Global health/quality of life mean baseline scores ranged between 44.7 and 55.4 (Reck et al, 2006;Hermes et al, 2008;Rolke et al, 2008;Lee et al, 2009). One study however reported baseline scores that were over 10 points higher, at 66 points.…”

“…Global HRQoL (Giaccone et al, 2005;Jatoi et al, 2005;Thatcher et al, 2005;Eckardt et al, 2006Eckardt et al, , 2009O'Brien et al, 2006;Reck et al, 2006Reck et al, , 2012Fennell et al, 2007;Bottomley et al, 2008;Hermes et al, 2008;Rolke et al, 2008;Westerman et al, 2008;Araujo et al, 2009;Lee et al, 2009;Slotman et al, 2009;Le Pechoux et al, 2011;Nagel et al, 2011;Wolfson et al, 2011;Chen et al, 2012;Sekine et al, 2014) was most frequently measured using two items (overall health and overall QoL) in the EORTC QLQ-C30 (n = 13, 62%). In the LCSS, the second most frequently used PRO to measure the concept (n = 4, 19%, Jatoi et al, 2005;Eckardt et al, 2006Eckardt et al, , 2009Chen et al, 2012), global QoL is assessed via a single item.…”